Journal Club
Open Access Article

Infusion Reactions

Wendy H. Vogel

infusions, Assessment, diagnosis, management
CJON 2010, 14(2), E10-E21. DOI: 10.1188/10.CJON.E10-E21

Many cancer therapies administered by IV infusion, including monoclonal antibodies, have the potential for infusion reactions. All infusion reactions involve the immune system; however, some (anaphylactic) are allergic in nature and usually are mediated by immunoglobulin E (lgE), whereas others (anaphylactoid) are not true allergic reactions and are not mediated by lgE. Although reactions can be allergic or nonallergic, the clinical manifestations are the same and require prompt, accurate assessment and astute management to avoid severe adverse events, including fatality. Monoclonal antibodies have a unique side-effect profile that includes the potential for nonallergic infusion reactions caused by cytokine release. Understanding the pathophysiology underlying any infusion reaction will enhance decision making regarding rechallenge and thereby improve treatment outcomes. Rituximab is an example of a drug with the potential for varying types of infusion reactions. This article discusses oncology nurses' role in patient risk assessment, institution of prophylactic measures, administration monitoring, severity grading, management, and follow-up. This understanding will clarify new data regarding the safety of a rapid infusion schedule of rituximab.

Jump to a section


    Amgen Inc. (2008). Vectibixa (panitumumab) [Package insert]. Thousand Oaks, CA: Author.
    Bello, C., & Sotomayor, E.M. (2007). Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology, 2007, 233-242. doi: 10.1182/asheducation-2007.1.233
    Berlex Laboratories. (2001). Campatha (alemtuzumab) [Package insert]. Richmond, CA: Author.
    Breslin, S. (2007). Cytokine-release syndrome: Overview and nursing implications. Clinical Journal of Oncology Nursing, 11(1, Suppl.), 37-42. doi: 10.1188/07.CJON.S1.37-42
    Bristol-Myers Squibb. (2007a). Paraplatina (carboplatin aqueous solution) injection [Package insert]. Princeton, NJ: Author.
    Bristol-Myers Squibb. (2007b). Taxola (paclitaxel) injection [Package insert]. Princeton, NJ: Author.
    Bristol-Myers Squibb. (2009). Erbituxa (cetuximab) solution for intravenous injection [Package insert]. Princeton, NJ: Author.
    Brown, S.G., Mullins, R.J., & Gold, M.S. (2006). Anaphylaxis: Diagnosis and management. Medical Journal of Australia, 185, 283-289.
    Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., … Flinn, I.W. (2001). Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology, 19, 2153-2164.
    Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., … White, C.A. (1999). Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology, 17, 791-795.
    Chung, C.H. (2008). Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist, 13, 725-732. doi: 10.1634/theoncologist.2008-0012
    Coiffier, B., Feugier, P., Mounier, N., Franchi-Rezgui, P., Van Den Neste, E., Macro, M., … Tilly, H. (2007). Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients [Abstract 8009]. Retrieved from
    Coiffer, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., … Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242. doi: 10.1056/NEJMoa011795
    Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., … Levy, R. (2000). Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135-3143.
    Davis, T.A., White, C.A., Grillo-Lopez, A.J., Velasquez, W.S., Link, B., Maloney, D.G., … Levy, R. (1999). Single-agent monoclonal antibody efficacy in bulk y non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. Journal of Clinical Oncology, 17, 1851-1857.
    Dillman, R.O., & Hendrix, C.S. (2003). Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Supportive Cancer Therapy, 1, 38-48. doi: 10.3816/SCT.2003.n.003
    Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., … Shaw, T. (2004). Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine, 350, 2572-2581. doi: 10.1056/NEJMoa032534
    Genentech, Inc. (2008). Avastina (bevacizumab) [Package insert]. San Francisco, CA: Author.
    Genentech, Inc. (2009). Herceptina (trastuzumab) [Package insert]. San Francisco, CA: Author.
    Genentech, Inc. (2010). Rituxana (rituximab) [Package insert]. San Francisco, CA: Author.
    Gobel, B.H. (2005). Chemotherapy-induced hypersensitivity reactions. Oncology Nursing Forum, 32, 1027-1035. doi: 10.1188/04.ONF.1027-1035
    Hallek, M., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M. … Fischer, K. (2008). Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [Abstract]. Blood, 112, 125.
    Johnson, P., & Glennie, M. (2003). The mechanisms of action of rituximab in the elimination of tumor cells. Seminars in Oncology, 30(1, Suppl. 2), 3-8. doi: 10.1053/sonc.2003.50025
    Kang, S.P., & Saif, M.W. (2007). Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer—Identification, prevention, and management. Journal of Supportive Oncology, 5, 451-457.
    Kemp, S.F., Lockey, R.F., & Simons, F.E. (2008). Epinephrine: The drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy, 63, 1061-1070. doi: 10.1111/j.1398-9995.2008.01733.x
    Kimby, E. (2005). Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews, 31, 456-473. doi: 10.1016/j.ctrv.2005.05.007
    Kohler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
    Lenz, H.J. (2007). Management and preparedness for infusion and hypersensitivity reactions. Oncologist, 12, 601-609. doi: 10.1634/theoncologist.12-5-601
    Li, H., Ayer, L.M., Lytton, J., & Deans, J.P. (2003). Store-operated medication entry mediated by CD20 in membrane rafts. Journal of Biological Chemistry, 278, 42427-42434.
    Lieberman, P., Kemp, S.F., Oppenheimer, J., Lang, D.M., Bernstein, I.L., Nicklas, R.A., … Fink, J. (2005). The diagnosis and management of anaphylaxis: An updated practice parameter. Journal of Allergy and Clinical Immunology, 115(3, Suppl. 2), S483-S523. doi: 10.1016/j.jaci.2005.01.010
    Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., … Levy, R. (1997). IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 15, 3266-3274.
    Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., … Levy, R. (1997). IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
    Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994). Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457-2466.
    Maloney, D.G., Smith, B., & Appelbaum, F.R. (1996). The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood, 88, 637.
    Mathas, S., Rickers, A., Bommert, K., Dorken, B., & Mapara, M.Y. (2000). Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways. Cancer Research, 60, 7170-7176.
    McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., & Dallaire, B.K. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
    National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events [v3.0]. Retrieved from
    O'Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., … Keating, M.J. (2001). Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 2165-2170.
    Oldham, R.K., & Dillman, R.O. (2008). Monoclonal antibodies in cancer therapy: 25 years of progress. Journal of Clinical Oncology, 26, 1774-1777.
    O'Neil, B.H., Allen, R., Spigel, D.R., Stinchcombe, T.E., Moore, D.T., Berlin, J.D., & Goldberg, R.M. (2007). High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. Journal of Clinical Oncology, 25, 3644-3648.
    Osterborg, A., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmen, A., … Wierda, W.G. (2008). Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial [Abstract]. Blood, 112, 126.
    Peereboom, D.M., Donehower, R.C., Eisenhauer, E.A., McGuire, W.P., Onetto, N., Hubbard, J.L., … Rowinsky, E.K. (1993). Successful retreatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology, 11, 885-890.
    Piro, L.D., White, C.A., Grillo-Lopez, A.J., Janakiraman, N., Saven, A., Beck, T.M., … Jain, V. (1999). Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 10, 655-661.
    Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., … Anderson, D.R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435-445.
    Rieger, P.T. (2001). Biotherapy: An overview. In P.T. Rieger (Ed.), Biotherapy: A comprehensive review (pp. 3-37). Sudbury, MA: Jones and Bartlett.
    Riley, J.K., & Sliwkowski, M.X. (2000). CD20: A gene in search of a function. Seminars in Oncology, 27(6, Suppl. 12), 17-24.
    Saif, M.W. (2006). Hypersensitivity reactions associated with oxaliplatin. Expert Opinion on Drug Safety, 5, 687-694. doi: 10.1517/14740338.5.5.687
    Salar, A., Casao, D., Cervera, M., Pedro, C., Calafell, M., Abella, E., … Besses, C. (2006). Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. European Journal of Haematology, 77, 338-340. doi: 10.1111/j.1600-0609.2006.00713.x
    sanofi-aventis U.S. LLC. (2008). Taxoterea (docetaxel) injection concentrate [Package insert]. Bridgewater, NJ: Author.
    sanofi-aventis U.S. LLC. (2009). Eloxatina (oxaliplatin powder for solution) [Package insert]. Bridgewater, NJ: Author.
    Schulz, H., Bohlius, J.F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., … Engert, A. (2007). Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. Journal of the National Cancer Institute, 99, 706-714. doi: 10.1093/jnci/djk152
    Sehn, L.H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K.K., Runzer, N., … Connors, J.M. (2007). Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood, 109, 4171-4173.
    Shan, D., Ledbetter, J.A., & Press, O.W. (2000). Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology, Immunotherapy, 48, 673-683.
    Siano, M., Lerch, E., Negretti, L., Zucca, E., Rodriguez-Abreu, D., Oberson, M., … Ghielmini, M. (2008). A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clinical Cancer Research, 14, 7935-7939. doi: 10.1158/1078-0432.CCR-08-1124
    Sliesoraitis, S., & Chikhale, P.J. (2005). Carboplatin hypersensitivity. International Journal of Gynecological Cancer, 15, 13-18.
    Solomon, S., & Komanduri, K. (2001). The immune system. In P.T. Rieger (Ed.), Biotherapy: A comprehensive review (pp. 39-63). Sudbury, MA: Jones and Bartlett.
    Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.A., … Keating, M.J. (2008). Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 112, 975-980. doi: 10.1182/blood-2008-02-140582
    Vial, T., & Descotes, J. (1995). Immune-mediated side-effects of cytokines in humans. Toxicology, 105, 31-57.
    Weiss, R.B. (1992). Hypersensitivity reactions. Seminars in Oncology, 19, 458-477.
    Zanotti, K.M., & Markman, M. (2001). Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety, 24, 767-779.